Suppr超能文献

肾移植受者中新冠病毒感染康复后的心血管疾病风险

Post-COVID-19 cardiovascular disease risk in kidney transplant recipients.

作者信息

Bowring Mary G, Manothummetha Kasama, Kittipibul Veraprapas, Li Lucy X, Avery Robin K, Cochran Willa, Ellis Sean, Wittstein Ilan S, Segev Dorry L, Durand Christine M, Brennan Daniel C, Permpalung Nitipong

机构信息

Department of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

出版信息

Am J Transplant. 2025 Jul 15. doi: 10.1016/j.ajt.2025.07.2462.

Abstract

Given the unique risk profile of kidney transplant recipients (KTRs), characterizing their cardiovascular disease (CVD) risk after COVID-19 remains critical for targeted management. We performed a retrospective analysis of 809 clinically diagnosed symptomatic COVID-19 events among 778 KTRs from a health system in Maryland (March 2020 to January 2024) to characterize incidence and risk factors of post-COVID-19 CVD. We followed KTRs until composite CVD (acute coronary syndrome, stroke, heart failure, and CVD-related death) occurrence, non-CVD-related death, or 1 year after COVID-19 and identified risk factors using least absolute shrinkage and selection operator-based subdistribution hazards regression. Incidence of post-COVID-19 CVD was 8.7% at 1 year (acute coronary syndrome, 2.7%; stroke, 1.4%; heart failure, 3.6%; and CVD-related death, 1.0%). KTRs with a CVD history had higher incidence than those without (19.1% vs 5.0%). Older age, Black race, Hispanic ethnicity, previous CVD, and COVID-19 hospitalization increased post-COVID-19 CVD risk; body mass index of >30 kg/m and treatment with remdesivir decreased post-COVID-19 CVD risk. COVID-19 hospitalization conferred equivalent risk to previous CVD: incidence was 11.2% among KTRs with previous CVD but no hospitalization, 12.0% among KTRs with hospitalization but no previous CVD, 25.2% among KTRs with both, and 1.8% among KTRs with neither. Post-COVID-19 CVD risk was high among KTRs and hospitalization for COVID-19 was as important as having had a previous cardiovascular event.

摘要

鉴于肾移植受者(KTRs)独特的风险状况,明确他们在感染新冠病毒后心血管疾病(CVD)的风险对于针对性管理至关重要。我们对马里兰州一个医疗系统中778名KTRs的809例临床诊断为有症状的新冠病毒感染事件进行了回顾性分析(2020年3月至2024年1月),以明确新冠病毒感染后CVD的发病率和风险因素。我们对KTRs进行随访,直至出现复合CVD(急性冠状动脉综合征、中风、心力衰竭和CVD相关死亡)、非CVD相关死亡或新冠病毒感染后1年,并使用基于最小绝对收缩和选择算子的亚分布风险回归来确定风险因素。新冠病毒感染后1年CVD的发病率为8.7%(急性冠状动脉综合征为2.7%;中风为1.4%;心力衰竭为3.6%;CVD相关死亡为1.0%)。有CVD病史的KTRs的发病率高于无病史者(19.1%对5.0%)。年龄较大、黑人种族、西班牙裔、既往CVD和新冠病毒感染住院会增加新冠病毒感染后CVD风险;体重指数>30 kg/m²和使用瑞德西韦治疗会降低新冠病毒感染后CVD风险。新冠病毒感染住院与既往CVD的风险相当:既往有CVD但未住院的KTRs中发病率为11.2%,有住院但无既往CVD的KTRs中发病率为12.0%,两者皆有的KTRs中发病率为25.2%,两者皆无的KTRs中发病率为1.8%。KTRs中新冠病毒感染后CVD风险较高,且新冠病毒感染住院与既往心血管事件同样重要。

相似文献

3
Smoking cessation for secondary prevention of cardiovascular disease.戒烟对心血管疾病二级预防的作用。
Cochrane Database Syst Rev. 2022 Aug 8;8(8):CD014936. doi: 10.1002/14651858.CD014936.pub2.
6
Belatacept for kidney transplant recipients.用于肾移植受者的贝拉西普。
Cochrane Database Syst Rev. 2014 Nov 24;2014(11):CD010699. doi: 10.1002/14651858.CD010699.pub2.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验